PCM
IMRX icon

Prelude Capital Management’s Immuneering IMRX Stock Holding History

Prelude Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,219
Closed -$154K – 1380
2026
Q1 		$154K Sell
29,219
-50,781
-63% -$260K 0.01% 971
2025
Q4 		$526K Buy
80,000
+7,533
+10% +$48.4K 0.04% 510
2025
Q3 		$507K Buy
+72,467
New +$376K 0.04% 503

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Prelude Capital Management's IMRX Position: Q2 2026 in Review

Prelude Capital Management sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 29,219 shares — an estimated $154K sold.

Prelude Capital Management first reported a position in IMRX in Q3 2025 and held it in 3 quarters. The position peaked at $526K in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Prelude Capital Management reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 29,219 Immuneering shares in Q2 2026, an estimated $154K.
  • Prelude Capital Management first reported a position in Immuneering in Q3 2025 and held it in 3 quarters.
  • Prelude Capital Management's Immuneering position peaked at $526K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.